CENTESSA PHARMACEUTICALS (260) — Strategic Asset Allocation Index

Latest as of March 2026: 52.8%

CENTESSA PHARMACEUTICALS (260) has a Strategic Asset Allocation Index of 52.8% as of March 2026. Strategic assets (PP&E of €- plus long-term investments of €257.12 Million) total €257.12 Million, measured against net assets of €487.35 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see 260 market cap overview.

SAAI

52.8%
Strategic Assets / Net Assets

Strategic Assets

€257.12 Million
PP&E + LT Investments

PP&E

€-
EUR

Net Assets

€487.35 Million
EUR

CENTESSA PHARMACEUTICALS Strategic Asset Allocation Index (2024–2025)

This chart shows how CENTESSA PHARMACEUTICALS's Strategic Asset Allocation Index has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the index stands at 52.8%, representing strategic assets of €257.12 Million against net assets of €487.35 Million EUR. See CENTESSA PHARMACEUTICALS (260) balance sheet quality index to measure how much of total assets are equity-financed.

Annual Strategic Asset Allocation Index for CENTESSA PHARMACEUTICALS (2024–2025)

The table below presents the year-by-year Strategic Asset Allocation Index for CENTESSA PHARMACEUTICALS from 2024 to 2025, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore CENTESSA PHARMACEUTICALS annual equity growth to track the company's year-over-year net asset growth rate.

Year SAAI Strategic Assets (EUR) PP&E LT Investments Net Assets Change (pp)
2025 53.6% €282.55 Million €- €282.55 Million €526.86 Million ▲ +53.6 pp
2024 0.0% €0.00 €- €0.00 €401.55 Million
pp = percentage points